Cargando…
From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
Autor principal: | Honavar, Santosh G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933873/ https://www.ncbi.nlm.nih.gov/pubmed/33463558 http://dx.doi.org/10.4103/ijo.IJO_150_21 |
Ejemplares similares
-
Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011) -
Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022) -
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021) -
Biobetters From an Integrated Computational/Experimental Approach
por: Kuyucak, Serdar, et al.
Publicado: (2017) -
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
por: Strohl, William R.
Publicado: (2015)